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Duchenne muscular dystrophy (DmD) is a fatal muscle wasting disease caused by a loss of the 
dystrophin protein. Control of dystrophin mRnA splicing to convert severe DmD to a milder 
phenotype is attracting much attention. Here we report a dystrophinopathy patient who has 
a point mutation in exon 31 of the dystrophin gene. Although the mutation generates a stop 
codon, a small amount of internally deleted, but functional, dystrophin protein is produced in 
the patient cells. An analysis of the mRnA reveals that the mutation promotes exon skipping 
and restores the open reading frame of dystrophin. Presumably, the mutation disrupts an exonic 
splicing enhancer and creates an exonic splicing silencer. Therefore, we searched for small 
chemicals that enhance exon skipping, and found that TG003 promotes the skipping of exon 31 
in the endogenous dystrophin gene in a dose-dependent manner and increases the production 
of the dystrophin protein in the patient’s cells. 
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D
uchenne muscular dystrophy (DMD) is the most common 
inherited muscle disease and is caused by a mutation in the 
dystrophin gene, the largest in the human genome, on the   
X  chromosome1.  Because  of  progressive  muscle  wasting,  DMD 
patients usually succumb to cardiac or respiratory failure in their 
twenties. Becker muscular dystrophy (BMD) is a milder allelic vari-
ant of DMD, usually affecting adult males. A reading frame rule 
explains the difference between DMD and BMD. Nonsense muta-
tions or deletions causing frame shifts in the dystrophin mRNA, 
both of which create premature termination codons (PTCs), usually 
result in a severe DMD phenotype, because of a lack of the dystrophin 
protein. In contrast, mutations/deletions that maintain the original 
reading frame in the mRNA cause the milder BMD phenotype, as 
a mutated, but still functional, dystrophin protein can be expressed 
from the mRNA2. However, in some mild BMD cases, the patients 
had nonsense mutations in exons but still produced novel in-frame 
dystrophin mRNAs by skipping the exons containing the nonsense 
codon3–7. Thus, internally deleted but partially functional dystrophin 
proteins can be produced from the exon-skipped mRNAs.
The current major therapeutic approach established by us, as 
well as by other groups, is to convert DMD to BMD phenotypes by 
restoring dystrophin protein expression by inducing exon skipping 
with antisense oligonucleotides (AONs)8–11. Several different AONs 
have been designed against either splice sites or splicing enhancer 
elements to induce exon skipping in cells of DMD patients. The 
AONs, which are designed to target those splicing elements, were 
demonstrated to restore the reading frame of dystrophin by caus-
ing skipping of the target exons. For example, the administration 
of an AON against an exonic splicing enhancer (ESE) in exon 19 
promoted exon skipping in cells and increased production of an 
internally  deleted  dystrophin  protein12–14.  Another  AON  against 
exon 51 is currently under clinical trials9,15,16. However, considering 
the therapeutic cost and convenience, small chemical compounds 
have been highly awaited. A small compound PTC124 (refs 17 and 
18), which induces read-through of the PTC, was reported to have 
the potential to treat some DMD patients who have nonsense muta-
tions. Although a clinical trial of PTC124 for DMD patients who 
have nonsense mutations in the dystrophin gene was completed, no 
significant improvement of treated patients was observed (http://
www.ptcbio.com/May_DBMD_Trial_Update.htm).
We have been interested in the role of phosphorylation of SR pro-
teins in splicing regulation. SR proteins are heavily phosphorylated 
in cells and are involved in constitutive and alternative splicing19,20. 
By extensive screening of 100,000 chemical compounds in a chemi-
cal library using in vitro phosphorylation assay, we identified several   
synthetic  chemical  compounds  that  inhibit  SR  protein  kinases   
specifically. We first identified a synthetic compound as a specific 
inhibitor of SR protein kinases and named it as SRPIN340 (ref. 21). 
Administration of SRPIN340 to mice retina changed the splicing 
pattern of vascular endothelial growth factor-A and suppressed vas-
cular generation22. We next identified TG003, a kinase inhibitor spe-
cific for Cdc-like kinases (Clks)22 that are also able to phosphorylate 
SR proteins. TG003 affected splicing both in vitro and in vivo23,24. 
Recently, we reported that spliceostatin, originally characterized as 
an antitumour drug, blocked splicing and promoted the export of 
unspliced pre-mRNAs25,26.
Here we tested these compounds to determine whether splic-
ing in this context in ex vivo myoblast cell culture could be modi-
fied, and found that TG003 enhanced exon skipping and produced   
an  internally  deleted  dystrophin  protein  in  the  in  vitro-formed   
myotubes of a dystrophinopathy patient who has a point mutation 
in exon 31 of the dystrophin gene.
Results
Point mutation causes skipping of exon 31 in a DMD patient. 
We have analysed and identified mutations in the dystrophin gene 
of more than 400 dystrophinopathy patients. We found that one 
patient (KUCG797) had a point mutation in exon 31. The mutation 
is a change from G to T (G to U on RNA) at position 4303 of the 
dystrophin cDNA (c.4303G > T, Fig. 1a). As this change replaced 
GAG for glutamate with the TAG for a stop codon (p.Glu1435X), 
the patient was not expected to produce dystrophin, resulting in 
severe DMD. The immunostaining of a biopsied skeletal muscle, 
however, showed patchy and discontinuous signals with antibodies 
recognizing  N-  or  C-terminal  dystrophin  domains  (Fig.  1e,f), 
which are comparable to BMD. Size and shape of muscle fibres were 
heterogeneous.
To  explain  the  discrepancy  between  the  genotype  and  the 
immunostaining pattern, we presumed that the nonsense muta-
tion in exon 31 disrupted the ESE, which resulted in skipping of the 
mutated exon in the patient’s muscle cells. To test this possibility, we 
analysed the dystrophin mRNA in skeletal muscle. The reverse tran-
scription polymerase chain reaction (RT–PCR) amplification of the 
region extending from exon 27 to exon 32 showed two nearly equal 
amounts of two products: one of expected size with exons 27–32, 
including the TAG stop codon in exon 31, and the other a smaller 
product  lacking  exon  31  (Fig.  1h,i).  However,  the  other  introns   
of  this  dystrophin  gene,  which  consists  of  79  exons,  seemed  to   
be  correctly  spliced  out  (Supplementary  Fig.  S1,  ( − )  lanes  and   
Supplementary Table S1). The resulting dystrophin mRNA lack-
ing the 111-bp-long exon 31 was in-frame to produce an internally 
deleted, but likely functional, dystrophin protein.
In  the  patient’s  muscle  cells,  the  exon  31-containing  mRNA 
should be lost by NMD, and only the internally deleted protein 
transcribed from the exon 31-skipped transcript can be expressed. 
Therefore, the dystrophin protein was immunostained with anti-
bodies  against  the  N-  or  C-terminal  domains  of  dystrophin   
(Fig. 1b,c,e,f), but failed to be recognized by MANDYS1, a mono-
clonal antibody against the exon 31-encompassing region in the 
patient’s cells (Fig. 1d,g).
Splicing regulators involved in exon 31 splicing.  These  results 
suggest that the point mutation in exon 31 not only produces a 
stop  codon  but  also  modifies  an  exonic  splicing  regulatory  site. 
To test this hypothesis, we incorporated the wild-type and mutant   
dystrophin gene fragment that retains exon 31 and the flanking introns 
into the H492 vector, which has been used for splicing analysis in 
cells (Fig. 1j)27–29, and transfected them into HeLa cells. Two PCR 
products were detected with the mutant plasmid (Fig. 1k), whereas 
only a single RT–PCR product was amplified from the wild-type 
plasmid. Sequencing analysis revealed that the smaller PCR product 
from the mutant does not include exon 31 (data not shown).
As mutant exon 31 with flanking introns cloned into the H492 
vector is sufficient to promote skipping, we tried to identify the 
splicing regulatory factors that bind to the RNA portion. According 
to  the  SpliceAid  program  (http://www.introni.it/splicing.html)30, 
exon 31 has the binding sequence of SRp30c/SRSF9 identified by 
SELEX (Supplementary Fig. S2b)31. The point mutation found in the 
patient disrupts the binding site of SRp30c/SRSF9, a member of the 
SR protein family (Supplementary Fig. S2a), which are often purine-
rich and known to bind to ESEs. In addition, the mutation presum-
ably generates an RNA sequence that has high homology to exonic 
splicing silencers (ESSs) recognized by the heterogeneous nuclear   
ribonucleoproteins  (hnRNPs)  A1  (Supplementary  Fig.  S2a,b)32.   
To test this notion, we first compared the binding to hnRNP A1 of the 
mutant RNA with that of the wild-type RNA in a gel mobility shift 
assay. The recombinant hnRNP A1 was prepared as a glutathione   
S-transferase (GST)-tagged protein (Supplementary Fig. S3b, lane 3)   
and mixed with either the wild-type or mutant dystrophin RNA,   
and the resultant complexes were analysed by native polyacryla-
mide gel electrophoresis. As shown in Figure 2a, two hnRNP A1–
RNA complexes showed different patterns of migration on the gel ARTICLE     
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(lanes 3–5 and 8–10). The faster-migrating complex contains one   
hnRNP A1 molecule on the RNA probe, whereas the slower-migrating   
complex  includes  more  than  two  hnRNP  A1  molecules33.   
The faster-migrating complex could be detected with both the wild-
type and mutant RNA even at a low concentration of GST–hnRNP 
A1 (lanes 3 and 8), reflecting the efficiency of its formation with either 
RNA at the hnRNP A1-binding site conserved in exon 31 (ref. 5).   
In contrast, the slower-migrating complex was formed two times 
more efficiently with the mutant than with wild-type RNA at each 
concentration of GST–hnRNP A1 protein (compare lanes 3–5 and 
8–10), and the difference was most obvious at the highest protein 
concentration (0.5 µM; lanes 5 and 10). As the estimated hnRNP A1 
protein concentration in the HeLa nucleus is ~145 µM (hnRNP A1 
6–7×107 molecules per cell34,35, and 690 µm3 for the volume of the 
HeLa cell nucleus36), the second binding site of the mutant exon 31 
would be occupied by hnRNP A1 in vivo. As a control, GST alone 
was used for the assays and no binding was detected (Fig. 2a, lanes 
2 and 7).
Consistent with the low binding score for SRp30c predicted by 
a Splice Aid analysis, weak binding of the SRp30c protein to the 
wild-type RNA was detected in the gel mobility shift assay (Sup-
plementary Fig. S3a, lanes 3–5). However, the binding of SRp30c 
to the mutated RNA was 25–50% lower than that to the wild type 
(lane 8–10), indicating that the point mutation of exon 31 affects 
the recognition by SRp30c. All the results described above strongly 
suggested that the mutated exon 31 was not efficiently recognized as 
an exon in the context of splicing.
To confirm this, we carried out in vitro splicing assays. For the 
assays, we prepared pre-mRNA that contains either the wild-type 
or mutant exon 31 in the intronic region of chicken δ-crystallin 
(CDC) pre-mRNA37 (Fig. 2b). The production of spliced mRNA 
containing the wild-type exon 31 (black circle) was detected with 
CDC-dys Ex31w pre-mRNA after a 60-min incubation (Fig. 2b, 
lanes 3–5). In contrast, the production of mRNA containing exon 
31 from the CDC-dys Ex31m pre-mRNA was suppressed (Fig. 2b, 
lanes 8–10).
Next we investigated the effect of the overexpression of these 
RNA-binding  proteins  on  the  splicing  pattern  of  a  minigene   
in  HeLa  cells.  As  shown  in  Figure  1f  previously,  this  minigene 
produced mRNA both with and without exon 31 (Fig. 2c, mock).   
When SRp30c/SRSF9 was overexpressed, the rate of exon skipping 
was reduced (Fig. 2c,d, SRp30c/SRSF9). In contrast, overexpression 
of hnRNP A1 promoted exon skipping (Fig. 2c,d, hnRNP A1, and 
Supplementary Fig. S4a). Although hnRNP A1 is an abundant pro-
tein in HeLa cells, as mentioned previously, we could detect similar 
amount of the exogenous protein to that of the endogenous protein 
(Supplementary Fig. S4b). As a control, SRp75/SRSF4, another SR 
protein38, was used for the same assay, but failed to change the splic-
ing pattern (Fig. 2c,d, SRp75/SRSF4). These results indicated that 
the skipping of the exon 31 in the dystrophin RNA was promoted   
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Figure 1 | Point mutation in exon 31 of the dystrophin gene causes exon skipping and restores the open reading frame for an internally deleted protein. 
(a) A point mutation that was found in the dystrophin gene of patient KuCG797. The position of c.4303G > T (p.Glu1435X) in exon 31 is indicated by the 
bar. (b–g) Dystrophin expression in the control (b–d) and in the patient’s (e–g) muscles. Immunohistochemical examinations for C-terminal (DYs2), 
n-terminal (DYs3) and rod- (mAnDYs1) domains were carried out. Immunoreactivity for DYs2 (exons 77–79 of dystrophin) and DYs3 (exons 10–12 of 
dystrophin) (e, f) was somewhat patchy and weaker in the patient’s muscles as compared with the control cells (b, c). However, immunoreactivity for 
mAnDYs1, which recognizes exon 31/32 of the dystrophin was defective only in the patient (compare panels d, g). scale bar, 50 µm. (h) The RT–PCR 
products obtained from the control and patient were analysed on agarose gels. The RT–PCR products from the patient’s RnA contained an additional 
shorter product. The DnA sequences of these bands were analysed, and the structure of each PCR product is shown schematically at the right of the 
panel. (i) sequencing of the shorter product seen in (c) confirmed the skipping of exon 31 in the patient. (j) A schematic representation of the hybrid 
minigene plasmids that harbour either the wild-type (W) or mutated (m) exon 31 of the dystrophin gene. The minigene vector H492 encodes two cassette 
exons (A and B) and an intron sequence containing a multicloning site. The dystrophin gene region encompassing exon 31 with flanking introns was 
inserted into the NheI and BamHI sites in the intron region of H492. These plasmids were transfected into HeLa cells and the pre-mRnAs were transcribed 
from the cytomegalovirus (CmV) promoter (CmVp). (k) The RT–PCR products of wild-type (W) and mutant (m) mRnA that were recovered from 
transfected HeLa cells were visualized on agarose gel. Two different PCR products were detected only with H492-dys Ex31m plasmid. Glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) mRnA was used as a control for transfection efficiency. As negative controls, RT–PCR reactions without reverse 
transcriptase (RT − ) were performed for both RnAs from the reporters and GAPDH.ARTICLE
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by disruption of the SRp30c/SRSF9-dependent ESE and production 
of an hnRNP A1-dependent ESS in exon 31.
TG003 promotes skipping of a mutated exon 31 in HeLa cells. The 
fact that this patient can express an internally deleted but presum-
ably partially functional dystrophin protein made us look for chem-
ical compounds that promote the skipping of exon 31 for further 
production of the internally deleted protein to improve the patient’s 
condition. We screened for specific inhibitors of a variety of kinases 
and found several compounds that affect alternative splicing21. As 
these  chemicals  were  demonstrated  to  affect  alternative  splicing   
in vitro and in vivo, we investigated the effect of eight compounds on 
the mutated exon 31 using the H492 minigene vector (Supplemen-
tary Table S2). TG003 strongly induced the skipping of the mutated 
exon in comparison with SRPIN340 and the solvent alone (Fig. 3a,b,   
dimethylsulphoxide, TG003 and SRPIN340). To examine the effect 
of TG003 on the wild-type exon 31, we next incubated cells with 
different  concentrations  of  the  compound  after  transfection  of 
the minigene plasmids. As shown in Figure 3c, TG003 promoted   
the skipping of the mutated exon 31 in a dose-dependent manner 
(Fig. 3c), but did not affect splicing of the wild type even at 50 µM 
(Fig. 3c). By quantitative RT–PCR analysis, we found that the ratio 
of skipped mRNA to total spliced mRNAs was increased by TG003 
in a dose-dependent manner (Fig. 3d). We then looked for other 
patients who were sensitive to TG003, and found one patient whose   
mutated  exon  was  skipped  on  the  administration  of  TG003   
(Supplementary Fig. S5). This dystrophy patient has a point muta-
tion in exon 27 (c.3613delG (p.Glu1205LysfsX9)), which produces 
a premature termination codon via a frameshift. We cloned the 
 dystrophin gene fragment containing the mutant exon 27 and flank-
ing introns into the H492 vector and transfected the plasmid into 
HeLa cells. As shown in Supplementary Figure S5, exon 27-skipped 
mRNA production was promoted by TG003 in a dose-dependent 
manner with the mutant plasmid in HeLa cells, whereas splicing of 
the wild-type mRNA was not affected.
TG003 promotes dystrophin expression in the patient’s cells. As 
the results obtained with a minigene construct strongly suggested 
that TG003 could induce exon 31-specific skipping, we next exam-
ined the effect of TG003 on splicing of the dystrophin gene in myob-
lasts. Muscle cells obtained from the patient were cultured on dishes. 
Equivalent amounts of dystrophin mRNA with and without exon 
31 were detected by RT–PCR (Fig. 4a). When TG003 was added to 
these cells, it was shown by quantitative RT–PCR analysis that the 
ratio of exon 31-skipped mRNA to total mRNAs was increased in 
a concentration-dependent manner (Fig. 4b). To examine the effect 
of TG003 on the splicing of other dystrophin introns, we prepared a 
subset of primers to amplify all 79 exons of dystrophin. The results 
of RT–PCR with or without TG003 showed that all exons except 
exon 31 were included (Supplementary Fig. S1 and Supplementary 
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Figure 2 | The point mutation in exon 31 enhances binding to hnRNP A1 and exon skipping both in vitro and in vivo. (a) Gel mobility shift assays with 
GsT–hnRnP A1 and dystrophin exon 31 RnA. 32P-labelled dystrophin exon 31 RnA (wild type or mutant) was incubated with either GsT alone (GsT: lanes 
2 and 7, 400 ng) or with GsT-tagged hnRnP A1 (GsT–hnRnP A1: lanes 3–5 and 8–10; 100, 200 and 400 ng, respectively), and the resultant complexes 
were subjected to 8% native polyacrylamide gel electrophoresis. Lanes 1 and 6 show where RnA itself migrates on the gel (marked as Free RnA on the 
right of the panel). Complexes of hnRnP A1 and RnA are also indicated as Bound RnA. All incubations were carried out at 20 °C for 30 min. (b) In vitro 
splicing assays with pre-mRnAs that contain exon 31. 32P-labelled chicken δ-crystallin (CDC) pre-mRnA containing either wild-type (WT) or mutant 
(c.4303G > T) exon 31 in the intron was incubated with HeLa cell nuclear extracts at 30 °C for the time shown at the top of the panel. The RnA products 
were analysed by electrophoresis on 6% denaturing gel. The structures of the pre-mRnA and two different mRnAs are shown at the right of the panel. 
Boxes with numbers indicate exons, whereas the lines between boxes designate introns. The mRnA that includes exon 31 (closed circle) was produced 
more efficiently with CDC-dys Ex31 WT pre-mRnA than CDC-dys Ex31 c.4303G > T pre-mRnA. (c) Effect of overexpression of several RnA-binding 
proteins on the inclusion and skipping of the mutant exon 31. HeLa cells (3×106 cells) were cultured overnight and transfected with 150 ng of the mutant 
reporter plasmid used in Figure 1f in combination with 1.5 µg of the plasmid that expresses designated proteins with a Flag tag. RnAs were recovered and 
analysed by RT–PCR. The skipping of the mutated exon 31 was inhibited by sRp30c/sRsF9, but promoted by hnRnP A1. (d) Quantification of the ratio 
between exon skipping and inclusion for the RnA expressed from the mutant reporter plasmid in the presence of several RnA-binding proteins. Averages 
and standard deviations from three independent experiments are shown. *P < 0.005.ARTICLE     
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Table S1), indicating that TG003 selectively promotes skipping of 
the mutated exon 31 in the patient’s cells (or a mutated exon 27 in 
another patient).
Therefore, we next examine whether TG003 really increases the 
expression of the internally deleted, but functional, dystrophin pro-
tein in the patient’s cells. Western blotting with an antibody that 
specifically recognizes the C terminus of dystrophin showed that 
the administration of TG003 (7 µM) increased the protein expres-
sion (Fig. 4c). The ratio of dystrophin (C terminal) signal to desmin 
signal was increased more than double by TG003. The antibody spe-
cific for the peptide with exon 31 did not detect it, indicating that 
the dystrophin protein lacks an exon 31-coding peptide (Fig. 4c). 
Therefore, TG003 promoted the expression of an internally deleted 
dystrophin protein by inducing exon 31 skipping in cells derived 
carrying the c.4303G > T mutation.
Discussion
This  paper  describes  a  patient  with  dystrophinopathy  who  had 
a point mutation in exon 31 of the dystrophin gene. As the muta-
tion creates an in-frame stop codon, the mRNA was not expected 
to produce a protein. However, RT–PCR demonstrated that exon 
31 was skipped and the dystrophin mRNA was naturally generated 
in this patient, and an internally deleted dystrophin protein was 
produced (Fig. 1e–g). We found that the point mutation in exon 
31 disrupted the SRp30c-mediated ESE, and simultaneously cre-
ated an ESS bound to hnRNP A1. This case is similar to that of the 
survival of motor neuron 2 (SMN2) gene39–42. The SMN2 gene has 
a C/T transition compared with the SMN1 gene, which results in 
prevention of efficient exon 7 splicing. In these cases, either muta-
tions or polymorphisms in exons can affect splicing by disrupting 
a positive element and creating a negative element39–42. In addition 
to affecting ESE, the c.4303G > T mutation increased the number of 
hnRNP A1-binding sites in exon 31 of the dystrophin gene. There 
was already one hnRNP A1-binding site in exon 31, but this muta-
tion added another. The hnRNP A1 protein was shown to bind RNA 
cooperatively43, and this would be facilitated by two high-affinity 
binding  sites44.  In  our  case,  the  hnRNP  A1-cooperative  binding 
seems to be facilitated by the c.4303G > T mutation, affecting the 
recognition and skipping of exon 31, as shown in Figure 2. It is very 
likely that there are more diseases and mutant phenotypes caused by 
the disruption/creation of splicing elements, as alternative splicing 
is maintained by a balance of positive and negative cis-elements in 
conjunction with trans factors.
Our results demonstrated that TG003 promoted exon skipping 
only in the mutant exon 31, but not in the wild type. TG003 is a 
specific inhibitor for Clks23, and Clks have been shown to phospho-
rylate SR proteins24,45–48. SRp30c/SRSF9 is likely involved in the rec-
ognition of exon 31 for splicing (Fig. 2 and Supplementary Figs S2 
and S3) and can be a target of TG003. However, TG003 had no effect 
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Figure 3 | TG003 promotes skipping of mutated exon 31 in HeLa cells in a dose-dependent manner. (a) Effect of chemical compounds on exon 31 
skipping with a heterologous reporter construct in HeLa cells. After transfection of the reporter plasmid (H492-dys Ex31m) as given in Figure 2c, HeLa 
cells were incubated in the presence of the chemical compounds at 30 µm for 24 h. Dimethylsulphoxide (Dmso) was used as a negative control as it was 
used as a solvent of compounds. RnAs were recovered and analysed by RT–PCR. TG003, but not sRPIn340, promoted skipping of the mutated exon 31. 
(b) Quantification of the ratio between exon skipping and inclusion for the RnA products expressed from the mutant reporter plasmid in the presence of 
several RnA-binding proteins. Averages and standard deviations from three independent experiments are shown. *P < 0.0001. (c) RT–PCR of the RnA 
recovered from the reporter plasmid-transfected HeLa cells cultured in the presence of several concentrations of TG003. (d) Quantification of the ratio 
of exon skipping to total spliced for the RnA products expressed from the mutant reporter plasmid in the presence of several concentrations of TG003 by 
quantitative RT–PCR. Averages and standard deviations from three independent experiments are shown.
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Figure 4 | TG003 induces not only exon 31 skipping but also exon 31 
dystrophin protein expression in patient cells. (a) RT–PCR with RnA 
recovered from primary cultured muscle cells treated with different 
amounts of TG003. (b) Quantification of the ratio of exon skipping to total 
spliced for the RnA products expressed from the patient’s endogenous 
dystrophin gene by quantitative RT–PCR. Averages and standard deviations 
from three independent experiments are shown. (c) Western blotting 
of dystrophin protein expression in TG003-treated cells. Proteins were 
detected with antibodies recognizing either the C terminus of dystrophin 
or the peptide encoded by exon 31. The antibody against desmin indicated 
that equivalent numbers of the cells were used for this assay.ARTICLE
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on the splicing of the wild-type exon 31, in which SRp30c/SRSF9 is 
involved (Fig. 3c). We assume that SRp30c contributes to the inclu-
sion of the exon, but it is not phosphorylated by Clk in the nucleus. 
Therefore, TG003 had no effect on WT exon 31. Moreover, we have 
currently demonstrated that the overexpression of Clks results in 
the specific phosphorylation of SRp75/SRSF4 among SR proteins   
in vivo24. This means that not all SR proteins are phosphorylated by 
Clks. It has been reported that the roles of SR proteins in splicing are 
not always the same. Although it is generally assumed that SR pro-
teins promote the inclusion of exons, some SR proteins can cause the 
skipping of exons in several alternative splicing events19,20,49. Thus, 
it is possible that some SR protein(s), which is phosphorylated by 
Clks, remains dephosphorylated by TG003, and this protein coop-
erates with hnRNP A1 as a coinhibitor of the recognition of exon 31 
during splicing. Another possibility is that hnRNP A1 is a specific 
target of Clks, although there has been no evidence for this. Further 
experiments are required to examine these possible scenarios.
In this patient, skipping of the mutated exon 31 restores the open 
reading frame. Therefore, it is likely that an internally deleted, but 
functional, dystrophin protein is expressed (Fig. 1e–g). This strongly 
suggests that better clinical features could be expected if the skip-
ping is induced more efficiently to produce more of the internally 
deleted protein. We found that TG003, reported as a Clk-specific 
inhibitor, stimulated skipping of the exon in both a minigene con-
struct and the endogenous pre-mRNA in the patient’s cells. When 
we administered 10 µM of TG003 into HeLa and COS cells, no mor-
phological changes were observed and growth rate was not affected 
up to 3 days23. We also confirmed that TG003 had no cytotoxic-
ity in HeLa cells at the dosage used in Figure 3c (data not shown), 
and even in mice at up to 100 mg kg − 1 per day per os (Onogi H. and 
Hagiwara M., unpublished data). As shown in Figure 3c, TG003 
induced the skipping of the mutated exon 31, but did not affect the 
splicing of the wild type. The selectivity of the effect of TG003 may 
explain the weak toxicity of the compound. TG003 was recently 
shown to inhibit the replication of the influenza virus by modifying 
the processing of viral RNA in cells50. Although more preclinical 
studies with animal models are needed, TG003 is the first chemi-
cal compound that is verified to improve dystrophin production in   
in  vitro  patient-derived  myotubes.  We  thus  started  to  look  for 
patients sensitive to TG003, and found another dystrophy patient 
whose mutated exon was skipped (Supplementary Fig. S5). We hope 
that our findings will contribute towards the development of a ther-
apy of Duchenne muscular dystrophy.
Methods
Case. The proband (KUCG 797) was a 5-year-old boy born to healthy Japanese 
parents without any family history of muscle disease. He started to walk independ-
ently at 1 year and 4 months of age and his motor development was normal.  
At the age of 2 years, his serum creatine kinase level was found to be 2,567 IU l − 1 
(normal  < 169 IU l − 1) in a routine blood examination conducted on admission to 
hospital. He was referred to Kobe University Hospital to have his dystrophin gene 
examined for mutations. The mild creatine kinase elevation persisted (1,331–
4,740 IU l − 1). No muscle weakness or abnormal gait was observed. At the age of 
5 years, a muscle biopsy was performed. Informed consent for all study aspects 
including genetic testing was obtained from the parents, and these studies were 
approved by our ethics committees.
Mutation analysis. DNA was isolated from blood samples by standard phe-
nol–chloroform extraction methods. Total RNA was isolated from peripheral 
lymphocytes that were collected from whole blood using Ficoll–Paque density gra-
dients (Amersham Biosciences AB) or from thin-sliced muscle sections of frozen 
muscle samples. RT–PCR and RT-nested PCR were used to analyse the dystrophin 
mRNA expressed in skeletal muscle. A region encompassing exons 27–32 was 
amplified using an inner set of primers (forward c27f and reverse 2F, Supplemen-
tary Table S1). The products were purified and sequenced either directly or after 
subcloning into the vector pT7 Blue-T (Novagen). The DNA sequences were deter-
mined using an automated DNA sequencer (model 310; Applied Biosystems).
Plasmid construction. To construct H492-dys Ex31w and H492-dys Ex31m, the 
fragments encompassing exon 31 and flanking intronic regions were amplified 
from the genomic DNA of both the control and the patient by PCR. The primers 
used were Int 30f-NheI: 5′-GCGGCTAGCGTGATCCACCTGCCTCGAC-3′ and 
Int 31r-BamHI: 5′-GCGGGATCCTCAAATCCAATCTTGCCAAT-3′. The ampli-
fied products were digested with NheI and BamHI (New England Biolabs), and  
inserted into the H492 that had been digested with the same restriction enzymes. 
For the construction of Flag-SRp30c and Flag-SRp75, PCR-amplified human 
SRp30c and mouse SRp75 cDNAs were inserted between the BamHI site and XhoI  
site of Flag-pCDNA3 (ref. 51), respectively. Human hnRNP A1 cDNA was ampli-
fied by PCR and inserted between the BamHI and NotI sites of Flag-pCDNA3  
(ref. 52) to construct Flag-hnRNP A1. To construct template plasmids for gel 
mobility shift assays, PCR-amplified wild-type and mutant dystrophin exon 31 
were cloned into the HindIII and XhoI sites of pCDNA3 (Invitrogen). The resultant 
plasmids were designated as pCDNA3–dys Ex31w and pCDNA3–dys Ex31m. For 
making pCDC–dys Ex31w and pCDC–dys Ex31m, the wild-type or mutant exon 
31 of the dystrophin gene was amplified by PCR and inserted between SacI and 
StyI sites of pCDC37. For protein expression in Escherichia coli, cDNAs for hnRNP 
A1 and SRp30c/SRSF9 lacking their termination codons were PCR-amplified and 
cloned between the BamHI and XhoI sites of pET-GSTII53. All plasmids described 
above were verified by sequencing.
Cell culture and transfection. HeLa cells were cultured as described previously37. 
Transfection of the plasmids was carried out by using Lipofectamine 2000 as  
recommended by the manufacturer. After 24 h of transfection, RNAs were recovered  
from the transfected cells. The chemical compounds were incubated for 24 h.
Primary culture of the DMD patient’s muscle cells. The patient’s muscle cells 
were cultured in DMEM (Sigma) supplemented with 20% fetal bovine serum 
(Gibco), 4% Ultrocer G (PALL) and 1% antibiotic-antimycotic (Gibco) in a six-well 
plate (gelatin-coated micro plate (six-well) with lid, IWAKI) until confluent. To in-
duce their differentiation into myotubes, the cells were cultured in DMEM (Sigma) 
supplemented with 2% horse serum (Gibco) and 1% antibiotic-antimycotic (Gibco) 
for 2 weeks with or without TG003. The medium and TG003 were refreshed every 
2 days.
Immunonohistochemical analyses of skeletal muscle. Skeletal muscle samples 
obtained from the rectus muscle of the thigh by biopsy were flash-frozen with 
isopentane cooled in liquid nitrogen. Serial 10-µm-thick frozen sections were 
analysed with histochemical staining. The procedure for the immunohistochemis-
try was as follows: serial 10-µm-thick frozen muscle sections were fixed in cold ac-
etone for 5 min. After blocking with normal goat serum, sections were incubated 
with primary antibodies overnight at 4 °C. The antibodies used were antidys-
trophin (DYS2: recognizing an epitope in exons 77–79, and DYS3: recognizing an 
epitope in exons 10–12, Novocastra) and antidystrophin (MANDYS1: recognizing 
an epitope in exon 31/32, a gift from Professor Dr Glenn E. Morris). After six 
rinses with PBS, sections were incubated with secondary antibodies, Alexa Fluor 
488-labelled goat anti-mouse or anti-rabbit antibodies, at room temperature for 
90 min.
Isolation of RNA and RT–PCR. RNA was isolated and analysed by RT–PCR, as  
described previously4. Primers used for amplification of dystrophin and human 
glyceraldehyde-3-phosphate dehydrogenase mRNAs are demonstrated in Supple-
mentary Table S1. PCR products were analysed on 2% agarose gels in Tris–borate/
EDTA buffer. Skipping efficiencies were determined from gel images by comparing 
the shortened dystrophin mRNAs to the intact transcript of full length in a densito-
metric analysis with Image J software (for patient samples) or by quantifying the 
skipped products with a DNA 1000 LabChip Kit on an Agilent 2100 bioanalyzer 
(Agilent Technologies; for hDMD mouse samples). Exon skip/inclusion ratios 
were calculated as the amount of skipped transcript relative to the full-length tran-
script. Where appropriate, a two-tailed Student’s t-test was used to determine the 
statistical significance of the skipping. As DNA size markers, φX174-HaeIII digest 
(TAKARA) or 2-Log DNA ladder (New England Biolab) was used for agarose gel 
electrophoresis.
Quantitative real-time RT–PCR. Real-time RT–PCR amplification was 
performed using a 7500 fast real-time PCR system (Applied Biosystems Inc.). 
Real-time PCR assays were carried out in a final volume of 20 µl consisting of 10 µl 
of TaqMan Fast Advanced Master Mix (Applied Biosystems Inc.), 18 pmol each 
of 5′ and 3′ primer, 5 pmol of specific probe and 10 ng of the sample cDNA. The 
real-time PCR conditions were as follows: 1 cycle for 20 s at 96 °C, followed by 40 
cycles of 2 s at 96 °C for denaturation, 15 s at 60 °C for annealing and 15 s at 72 °C 
for extension. Spectral data were captured and analysed using 7500 Real-Time 
Analysis Software version 2.0.3 (Applied Biosystems Inc.). All samples were run 
in triplicate. β-Actin and desmin was analysed as an endogenous RNA refer-
ence gene for normalization of H492-dys 31-derived mRNA and endogenous 
dystrophin mRNA from the patient, respectively. Exon skip/total ratios were 
calculated as the proportion of skipped transcript relative to both the full-length 
and the skipped transcripts.
The PCR primers and probes (5-FAM and 3-MGB) were designed with Primer 
Express software (Applied Biosystems Inc.), and the sequences of the primers and 
probes are shown in Supplementary Table S1.ARTICLE     
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Western blotting with the patient’s myotubes. The patient’s myotube cells were 
rinsed twice with PBS and then collected using 1× Cell Lysis Buffer (Cell Signaling 
Technology). Total protein (60 µg) was loaded on a 3–10% gradient polyacrylamide 
gel (PAGEL, ATTO). The fractionated proteins were transferred to HYBOND-P 
(GE Healthcare). Western blotting was performed using the ECL advance Western 
Blotting Detection kit (GE Healthcare) according to the manufacturer’s instruc-
tions. The membrane was incubated with an antibody against the C terminus 
(NCL-DYS2, Leica) and exon 31 (MANDYS8, a gift from Dr Glenn E. Morris) of 
dystrophin at a dilution of 1:10 and 1:100, respectively. The dystrophin–antidys-
trophin immune complexes were detected with anti-mouse IgG (GE Healthcare). 
Western blotting for desmin was performed using the same protocol as described 
above. The Desmin antibody (H-76, Santa Cruz) was used at a dilution of 1:50.  
The desmine–antidesmine immune complexes were detected with anti-rabbit IgG  
(GE Healthcare).
Preparation of recombinant proteins. All proteins were overexpressed in BL21 
(DE3) CodonPlus-RIPL cells (Stratagene). GST-His, GST-hnRNP A1-His and 
GST-SRp30c-His were induced at 20 °C overnight, purified according to the manu-
facturer’s instructions (Pharmacia) and dialysed against PBS. Dialysed proteins 
were further purified on nickel resin (Qiagen) as recommended by the manufac-
turer and dialysed against buffer E (20-mM HEPES-KOH pH 7.9, 100-mM KCl, 
0.2-mM EDTA, 10% glycerol and 1-mM DTT). Purified proteins were quickly 
frozen by liquid nitrogen and stored at  − 80 °C.
In vitro transcription and splicing assay. As templates, pCDNA3–dys Ex31 
and pCDNA3–dys Ex31m were linearized with XhoI, and pCDC–dys Ex31w and 
pCDC–dys Ex31m were linearized with SmaI. In vitro transcription and purifica-
tion of the transcribed RNAs were performed as described previously 37. HeLa cell 
nuclear extracts were obtained from Cilbiotech. In vitro splicing assay was carried 
out in a 10-µl scale as described previously37. The RNAs were analysed by 6% dena-
turing polyacrylamide gel electrophoresis and autoradiography.
Gel mobility shift assay. Gel mobility shift assays were essentially carried out 
as described previously54. The binding buffer that was used contained 16-mM 
HEPES-KOH (pH 7.9), 80-mM KCl, 0.16-mM EDTA, 0.8-mM DTT, 8% glycerol, 
100 ng µl − 1 of BSA, 50 ng µl − 1 of E. coli tRNA (Sigma Chemical Co.), 5×104 c.p.m. 
of RNA (dystrophin exon 31 wild type or mutant RNA) and 1 U µl − 1 of RNasin 
(Promega). Eight percent native polyacrylamide gels were used to analyse the 
complexes.
Statistical analyses. Statistical analyses were performed with Prism5 statistical 
software (GraphPad) using a paired t-test or a one-way analysis of variance, fol-
lowed by Tukey’s multiple comparison test. 
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